ArticleMMWR. Morbidity and mortality weekly report2004
Prevalence of overweight and obesity among adults with diagnosed diabetes--United States, 1988-1994 and 1999-2002.
Article in MMWR. Morbidity and mortality weekly report, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 102 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A 16-wk, Uni-center, Randomized, Double-blind, Parallel, Phase 3b Trial to Evaluate Efficacy of Saxagliptin + Dapagliflozin vs.Dapagliflozin With Regard to EGP in T2DM With Insufficient Glycemic Control on Metformin+/-Sulfonylurea Therapy
A Randomised Controlled Trial of a Duodenal Sleeve Bypass Device (EndoBarrier)Compared With Standard Medical Therapy for the Management of Obese Subjects With Type 2 Diabetes
HYbrid CoronAry Revascularization in DiabeticS: A Randomized Controlled Trial (Pilot)
Who cites it
102 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis.BMJ open diabetes research & care · 2022Pooled it
- Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.Diabetes, obesity & metabolism · 2026Trial
- Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects.International journal of clinical pharmacology and therapeutics · 2022Trial
- Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.Diabetes care · 2020Trial
- Effect of baseline body mass index on glycemic control and weight change with exenatide monotherapy in Chinese drug-naïve type 2 diabetic patients.Journal of diabetes · 2019Trial
- EndoBarrier®: a Safe and Effective Novel Treatment for Obesity and Type 2 Diabetes?Obesity surgery · 2018Trial
- Trial
- Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2013Trial
- Death cause and age at death among individuals with diabetes: a 40-year retrospective Brazilian study.Archives of endocrinology and metabolism · 2026Article
- Effects of exercise on cardiac structure and function in patients with type 2 diabetes: a narrative review of prospective imaging studies.The international journal of cardiovascular imaging · 2025Review
- High-Fat Diet and Altered Radiation Response.Biology · 2025Review
- Article
- Article
- The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China.Health economics review · 2024Article
- Evaluation of Anti-Obesity and Antidiabetic Activities ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Medicare drug price negotiation: The complexities of selecting therapeutic alternatives for estimating comparative effectiveness.Journal of managed care & specialty pharmacy · 2024Article
- Regulation of the Cortisol Axis, Glucagon, and Growth Hormone by Glucose Is Altered in Prediabetes and Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2024Article
- Diabetes-specific formula with standard of care improves glycemic control, body composition, and cardiometabolic risk factors in overweight and obese adults with type 2 diabetes: results from a randomized controlled trial.Frontiers in nutrition · 2024Article
- Targeting the Epigenetic Marks in Type 2 Diabetes Mellitus: Will Epigenetic Therapy Be a Valuable Adjunct to Pharmacotherapy?Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- The relationship between fat distribution and diabetes in US adults by race/ethnicity.Frontiers in public health · 2024Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity in persons with diabetes is associated with poorer control of blood glucose levels, blood pressure, and cholesterol, placing persons with diabetes at higher risk for both cardiovascular and microvascular disease. Conversely, intentional weight loss is associated with reduced mortality among overweight persons with diabetes. CDC analyzed the prevalence of overweight and obesity among U.S. adults aged >/=20 years with previously diagnosed diabetes by using data from two surveys: the Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994, and NHANES 1999-2002. This report summarizes the results of that analysis, which indicated that most adults with diagnosed diabetes were overweight or obese. During 1999-2002, the prevalence of overweight or obesity was 85.2%, and the prevalence of obesity was 54.8%. Encouraging patients to achieve and maintain a healthy weight should be a priority for all diabetes-care programs.
Indexed as
Identifiers
15549021What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.